Multiple Sclerosis is a neurodegenerative disease that may start in early adult life resulting from demyelination. There is appearance of scattered foci in the white matter of the central nervous system which is associated with axonal loss. The disease can be rapidly progress and is subject to remissions.
The disease is an autoimmune disease characterized by antibodies destroying the myelin sheaths around nerves.
Treatment by Stem Cell Genetic Med consists of the following:
- Autologous stem cells extracted from the patient’s peripheral blood or bone marrow are administered to the patient.
- Neuron stem cells are mixed with brain neuropeptide, nerve cell factor, neurotrophins, glial derived neurotrophins, oligodendrocytes and vascular endotherlial growth factor administered into the central nervous system through the spinal canal. Dendritic cells are part of the treatment to control and reduce autoimmune antibodies that destroy the nerve cell sheaths. The aim of this therapy is to cause remyelination of the affected diseased areas with the neuron stem cells and nerve cell growth factors.
- Glatiramer acetate (Copaxone) with daily subcutaneous injections has been shown to reduce the relapsing rate and reduce disability of multiple sclerosis patients with relapsing-remitting multiple sclerosis.
Patients are given oral and injectable agents to stimulate endogenous stem cells prior to the treatment and post treatment. Follow-up MRIs of the brain and spinal cord should be done six months after treatment. Intensive physical therapy plays an important role after stem cell treatment.